ETNB | 89bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.60 - 7.95
52 Week Range	6.43 - 16.63
Beta	0.97
Implied Volatility	71.27%
IV Rank	90.80%
Day's Volume	4,322,980
Average Volume	879,922
Shares Outstanding	117,582,000
Market Cap	933,601,080
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-11-11

Valuation
Profitability
Growth
Health
P/E Ratio	-2.68
Forward P/E Ratio	N/A
EPS	-2.96
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	70
Country	USA
Website	ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB's peers: ADMA, ALDX, ARCT, ASND, CABA, MDGL, PLRX, ACLX, STOK, DAWN, XFOR, INZY, ABOS, MREO, VKTX, ICPT, TERN, AKRO, RETA, HOOK, TGTX, HEPA, GALT, IMVT, LEGN, LGND, MRNS, PRTA, RVNC, VRDN, MLTX

*Chart delayed

Analyzing fundamentals for ETNB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see ETNB Fundamentals page.

Watching at ETNB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ETNB Technicals page.